April 27, 2017
Mellitus Reports Publication of Investigator-Initiated Study Supporting Glycated CD59 as a Novel Alternative for Gestational Diabetes Screening
-A single blood test to measure GCD59 at week 24-28 of gestation identified women with gestational diabetes with high sensitivity and specificity-
-GCD59 technology to advance diabetes detection and monitoring under exclusive license by Mellitus from Harvard University-
BOSTON, Mass., April 27, 2017 – Mellitus, LLC today reported the publication of results from a prospective, investigator-initiated study conducted at Brigham and Women’s Hospital (BWH) demonstrating the potential clinical utility of glycated CD59 (GCD59) as a novel biomarker for the screening and diagnosis of gestational diabetes mellitus (GDM). The data from this study showed that a single blood test that measures plasma GCD59 at week 24-28 of gestation identified women with GDM with high sensitivity and specificity. The study was completed by a team of investigators at BWH led by Jose A. Halperin, M.D., in collaboration with researchers from Harvard T.H. Chan School of Public Health. Dr. Halperin, scientific Co-founder of Mellitus, is a physician and researcher at BWH and Associate Professor of Medicine at Harvard Medical School (HMS). The paper titled, “Plasma Glycated CD59, a Novel Biomarker for Detection of Pregnancy-Induced Glucose Intolerance,” was published online ahead of print in the Novel Communications in Diabetes section of Diabetes Care, an American Diabetes Association journal.